This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Surgery in gastro-oesophageal reflux disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Fundoplication offers the possibility of curing oesophagitis and relieving symptoms without the need for long-term medication

  • laparoscopic funoplication
    • operation (fundoplication) involves partial (Toupet 270°) or total (Nissen 360°) wrapping of the fundus of the stomach around the lower oesophagus to recreate a high pressure zone
    • resolution of reflux symptoms is observed in up to 90% of patients
    • main side effects of the procedure includes dysphagia and bloating which may vary in severity from mild to severe (1)

Surgical treatment has a place in treating those who are (1):

  • refractory to or intolerant of medical therapy, or,
  • those with large-volume reflux
  • symptoms such as chronic cough that prove refractory to PPI treatment
  • possibly younger patients who wish to avoid life-long medication (1)

A randomised controlled trial (RCT) investigated the long term outcomes of surgical and medical treatments in patients with uncomplicated gastro-oesophageal reflux disease (GORD) (2):

  • design - randomised controlled trial; mean follow-up 10 years
  • patients - involved 247 patients (mean age of 58 years) with uncomplicated GORD. Follow-up analysis involved 129 of 160 surviving patients (mean age 67 years, 98% men)
  • intervention
    • surgical treatment (n=82) - Nissen fundoplication, or,
    • continuous medical treatment (n=77) - using ranitidine 150mg bd and metoclopramide 10 mg qds, sucralfate 1g in 10ml of warm water after meals when necessary for persistent symptoms, or,
    • symptomatic medical treatment, medication as in continuous treatment arm but used on as necessary basis, (n=88)
  • results
    • intention to treat analysis was used. For analysis purposes the 2 medical treatment groups were combined because of similar baseline characteristics, study treatments and outcomes
    • survival during a 140 month period was lower in the surgical group than the medical group (p=0.047)
    • surgical and medical treatments did not differ in the use of prokinetics (p=0.39) or subsequent antireflux surgery (p=0.38)
    • surgical treatment reduced the use of antireflux medications after the treatment period
    • after surgical treatment - 62% of patients returned to using medication for their GORD, and 32% returned to using proton pump inhibitors; however during the follow-up period 64% of patients treated with medications used proton pump inhibitors
  • conclusions:
    • this study provides evidence that, in patients with uncomplicated GORD, surgical treatment led to a reduction in the use of antireflux medication and decreased survival in comparison with medical treatment - the authors suggest that future studies need to prospectively address the lower survival rate in the surgical treatment group (60%) compared with that in the medical treatment group (72%)
    • there was no different in the rate of subsequent antireflux surgery in comparison of medical and surgical treatment

Grant et al (3) undertook a study that revealed:

  • in patients with chronic grastro-oesophageal reflux disease, a strategy of early laparoscopic surgery improved quality of life and reduced symptoms more than continued medical management at least up to 1 year after surgery

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.